How to Cite
Abstract
Anticancer treatment effects of E.coli phage lysate vaccinations (0,25 ml, 1x intraperitoneally, with 5 days interval) have been studied in 2-3 months old 30 lab. mice with Ehrlich carcinoma. The treatment efficacy was estimated by the dynamic of growth of cancer tissue and cancer growth inhibition percent. Immune system status was studied by measurement of IL-12 concentration with the use of ELISA. The trials have shown that E.coli phage lysate injections delay the cancer growth. Anticancer treatment effect was especially obvious and well expressed in case of 3 and 4 times vaccinations. During the same period increased secretion of IL- 12 in treated mice compared to the untreated and healthy control was detected. After 5-8 injections the anticancer action of the preparation decreased. Although the cancer volume in treated group animals was less than in the control’s one, the prolonged vaccinations supported further cancer growth. After 5-8 injections concentration of IL-12 was decreased as well. The peak of IL-12 secretion was reached on 3rd injection, but after 5-8 vaccinations there was no statistically significant difference between results of experimental and control group animals. Could be concluded that the bacterial preparation - E.coli phage lysate reveal anticancer immunomodulatory properties. For positive treatment results the detection of optimal dosage and regimen of vaccinations is important.
References
Bradford M. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72: 248- 254.
Chang, H. , Radbruch, A. The pro- and anti-inflammatory potential of interleukin-12. Ann. N. Y. Acad. Sci., 2007. 1109, 40–46.
Chanishvili N. Immune response to phage therapy. In: “A literature Review of the Practical Application of Bacteriophage Research”, Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi, Georgia, 2009, pp.107-112.
Chen ML, Pittet MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A. 2005;
Colombo M., Trinchieri, G. Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev., 2002, 13(2), 155–68.
Fokine A., Rossmann M. Molecular architecture of tailed double-stranded DNA phages. 2014, Bacteriophage.
Gambashidze KG, Khorava PA, Kalandarishvili KG, Lasareishvili BG, Dzhaiani EG, Azaladze AT, Tediashvili MI. [Application of bacterial thermo-and phagelysates for suppression of malignant tumor growth in experimental studies: 1. Anticancer efficacy of thermo- and phagelysates of E.coli]. Georgian Med News. 2012 Jan;(202):42-7. Russian. PMID: 22392782.
Gately M, Warrier R, Honasoge S., et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-ã in vivo. Int Immunol 1994;6:157–167.
Górski, A., Bocian, K., Borysowski, J., et al. LPSActivated Monocytes Are Unresponsive to T4 Phage and T4-Generated Escherichia coli Lysate. 2016. Front Microbiol., 7, 1356.
Hsieh C., Macatonia S., Tripp C., et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeriainduced macrophages. Science 1993;260:547–549.
Jackson J, Yan Y, Brunda MJ et al. Interleukin-12 enhances peripheral hematopoiesis in vivo. Blood. 1995; 85:2371–2376.
Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. 2006 Jul 15;177(2):896-904.
Kerkar S., Goldszmid R., Muranski P., et al. IL-12 triggers a programmatic change in dysfunctional myeloidderived cells within mouse tumors. J Clin Invest. 2011; 121:4746–4757.
Kerkar S., Leonardi A., van Panhuys N., et al. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther. 2013;21:1369–1377.
Manetti R., Parronchi P., Grazia M. et al. Natural killer cell stimulatory factor IL-12 induces T helper type 1 (Th1)- specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177:1199–1204.
Robertson M, Ritz J. Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment. The Oncologist February 1996; 1(1);2:88-97.
Tare N., Bowen S., Warrier R. et al. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J Interferon Cytokine Res 1995; 15:377–383.
Trinchieri, G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood, 1994; 84(12), 4008–27.
Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today. 1993;14:335–338
Watkins S., Egilmez N. Suttles J. IL-12 rapidly alters the functional profile of tumor-associated and tumorinfiltrating macrophages in vitro and in vivo. J Immunol, 2007; 178(3):1357–62.
Yang Z., Grote D., Ziesmer S. et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. The Journal of Clinical Investigations, 2012; 122(4):1271–1282.